Journal of Liver

Therapy with sartans significantly prolongs overall survival and delays time to recurrence in patients undergone radiofrequency ablation of hepatocarcinoma nodules

2^nd International Conference on Hepatology

May 09-11, 2016 Chicago, USA

Barone Michele and Facciorusso Antonio

University of Bari School of Medicine, Italy

Posters & Accepted Abstracts: J Liver

Abstract:

Background: Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim: The aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Methods: Data on 153 patients were reviewed. The study population was classified into 3 groups: 73 (47.8%) patients who received neither angiotensin-converting enzyme (ACE) inhibitors nor sartans (group 1), 49 (32%) patients treated with ACE inhibitors (group 2), and 31 (20.2%) patients treated with sartans (group 3). Survival outcomes were analyzed by means of Kaplan-Meier analysis and compared with log-rank test. Results: In the whole study population, 85.6% of patients were in Child-Pugh A class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10-40) and alpha fetoprotein was 25 (1.1-2100) UI/mL. No differences in baseline characteristics among the 3 groups were reported. Median overall survival was 48 months (95% confidence interval: 31-58) in group 1, 72 months (49-89) in group 2, and 84 months (58-92) in group 3 (P=0.02). Median time to recurrence was 26 (15-42), 44 (33-72), and 69 (44-74) months in the 3 groups, respectively (P=0.02). Sartan therapy was a significant predictor of longer overall survival and delayed time to recurrence on multivariate analysis. Conclusions: Sartans significantly improved overall survival and time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients.

Biography :

Email: michele.barone@uniba.it